|
Bausch Health To Reduce Debt By Additional $76 Million, Bringing Total Debt Repayment In Quarter To Approximately $400 Million
|
12/19/18
|
Bausch Health To Reduce Debt By Additional $76 Million, Bringing Total Debt Repayment In Quarter To Approximately $400 Million
|
PDF
|
|
Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
|
12/12/18
|
Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
|
PDF
|
|
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
|
12/05/18
|
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
|
PDF
|
|
Bausch Health Announces Redemption Of $200 Million Aggregate Principal Amount Of Its Outstanding 5.625% Senior Notes Due 2021
|
11/30/18
|
Bausch Health Announces Redemption Of $200 Million Aggregate Principal Amount Of Its Outstanding 5.625% Senior Notes Due 2021
|
PDF
|
|
Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021
|
11/27/18
|
Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021
|
PDF
|
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
|
11/21/18
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
|
PDF
|
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
11/19/18
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
|
Bausch + Lomb Reports More Than Five Million Units Of Contact Lens Materials Recycled By Second Anniversary Of ONE By ONE Recycling Program
|
11/15/18
|
Bausch + Lomb Reports More Than Five Million Units Of Contact Lens Materials Recycled By Second Anniversary Of ONE By ONE Recycling Program
|
PDF
|
|
Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland
|
11/13/18
|
Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland
|
PDF
|
|
Bausch Health Commences Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
|
11/07/18
|
Bausch Health Commences Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021
|
PDF
|
|
Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement
|
11/07/18
|
Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement
|
PDF
|
|
Bausch Health To Participate At The Stifel 2018 Healthcare Conference
|
11/07/18
|
Bausch Health To Participate At The Stifel 2018 Healthcare Conference
|
PDF
|
|
Bausch Health Announces U.S. Launch Of BRYHALI™ (halobetasol propionate) Lotion, 0.01%, For Plaque Psoriasis In Adults
|
11/07/18
|
Bausch Health Announces U.S. Launch Of BRYHALI™ (halobetasol propionate) Lotion, 0.01%, For Plaque Psoriasis In Adults
|
PDF
|
|
Bausch Health Companies Inc. Announces Third-Quarter 2018 Results
|
11/06/18
|
Bausch Health Companies Inc. Announces Third-Quarter 2018 Results
|
pdf
|
|
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
|
10/30/18
|
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
|
PDF
|
|
Dr. Andrew C. Von Eschenbach Joins Bausch Health Board Of Directors
|
10/30/18
|
Dr. Andrew C. Von Eschenbach Joins Bausch Health Board Of Directors
|
PDF
|
|
Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
|
10/29/18
|
Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
|
PDF
|
|
Bausch + Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite™ Vision Enhancement System On IBM Cloud
|
10/24/18
|
Bausch + Lomb To Launch First-In-Class Surgical Support Applications For Stellaris Elite™ Vision Enhancement System On IBM Cloud
|
PDF
|
|
Bausch Health Announces Endowment With The University Of Missouri To Support Student Scholarships
|
10/23/18
|
Bausch Health Announces Endowment With The University Of Missouri To Support Student Scholarships
|
PDF
|
|
Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference
|
10/15/18
|
Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference
|
PDF
|
|
Bausch Health Companies Inc. Will Release Third-Quarter 2018 Financial Results On November 6
|
10/12/18
|
Bausch Health Companies Inc. Will Release Third-Quarter 2018 Financial Results On November 6
|
PDF
|
|
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
|
10/11/18
|
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
|
PDF
|
|
Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting
|
10/08/18
|
Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting
|
PDF
|
|
Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
|
10/08/18
|
Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
|
PDF
|
|
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali™* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology
|
10/02/18
|
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali™* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology
|
PDF
|
|
Salix Resolves Legacy SEC Investigation With No Penalty
|
09/28/18
|
Salix Resolves Legacy SEC Investigation With No Penalty
|
PDF
|
|
Bausch Health Releases First Annual Corporate Social Responsibility Report
|
09/27/18
|
Bausch Health Releases First Annual Corporate Social Responsibility Report
|
PDF
|
|
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
|
09/27/18
|
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
|
PDF
|
|
Bausch Health Announces Redemption Of $125 Million Aggregate Principal Amount Of Its Outstanding 7.50% Senior Notes Due 2021
|
09/26/18
|
Bausch Health Announces Redemption Of $125 Million Aggregate Principal Amount Of Its Outstanding 7.50% Senior Notes Due 2021
|
PDF
|
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
09/24/18
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
|
Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation
|
09/12/18
|
Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation
|
PDF
|
|
Bausch Health Reduces Debt By Additional $107 Million, Eliminating All Remaining Mandatory Amortization For 2018
|
09/11/18
|
Bausch Health Reduces Debt By Additional $107 Million, Eliminating All Remaining Mandatory Amortization For 2018
|
PDF
|
|
Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies
|
09/11/18
|
Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies
|
PDF
|
|
LUMIFY™ Redness Reliever Eye Drops Honored By The National Association of Chain Drug Stores As Product Showcase Winner
|
09/10/18
|
LUMIFY™ Redness Reliever Eye Drops Honored By The National Association of Chain Drug Stores As Product Showcase Winner
|
PDF
|
|
Bausch Health Companies To Participate At The Morgan Stanley Global Healthcare Conference
|
09/06/18
|
Bausch Health Companies To Participate At The Morgan Stanley Global Healthcare Conference
|
PDF
|
|
Bausch + Lomb Announces Publication Of Pivotal Phase 3 Data On Loteprednol Etabonate Ophthalmic Gel, 0.38% In Journal Of Cataract And Refractive Surgery
|
09/05/18
|
Bausch + Lomb Announces Publication Of Pivotal Phase 3 Data On Loteprednol Etabonate Ophthalmic Gel, 0.38% In Journal Of Cataract And Refractive Surgery
|
PDF
|
|
US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference
|
09/04/18
|
US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference
|
PDF
|
|
FDA Accepts Resubmission Of New Drug Application For Duobrii™1 (Halobetasol Propionate And Tazarotene) Lotion
|
08/29/18
|
FDA Accepts Resubmission Of New Drug Application For Duobrii™1 (Halobetasol Propionate And Tazarotene) Lotion
|
PDF
|
|
Ortho Dermatologics Receives FDA Approval For ALTRENO™ (tretinoin 0.05%) Lotion For Acne
|
08/24/18
|
Ortho Dermatologics Receives FDA Approval For ALTRENO™ (tretinoin 0.05%) Lotion For Acne
|
PDF
|
|
Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII™ (halobetasol propionate and tazarotene) Lotion
|
08/15/18
|
Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII™ (halobetasol propionate and tazarotene) Lotion
|
PDF
|
|
Ortho Dermatologics Announces 2018 Aspire Higher Scholarship Recipients
|
08/08/18
|
Ortho Dermatologics Announces 2018 Aspire Higher Scholarship Recipients
|
PDF
|
|
Bausch Health Companies Inc. Announces Second-Quarter 2018 Results
|
08/07/18
|
Bausch Health Companies Inc. Announces Second-Quarter 2018 Results
|
pdf
|
|
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets
|
08/06/18
|
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets
|
pdf
|
|
Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center
|
08/03/18
|
Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center
|
pdf
|
|
Bausch Health Companies Will Release Second-Quarter 2018 Financial Results On August 7
|
07/18/18
|
Bausch Health Companies Will Release Second-Quarter 2018 Financial Results On August 7
|
pdf
|
|
Bausch Health Companies Inc. Begins Trading Today as "BHC" on NYSE and TSX
|
07/16/18
|
Bausch Health Companies Inc. Begins Trading Today as "BHC" on NYSE and TSX
|
pdf
|
|
Bausch Health Companies Inc. completes name change
|
07/13/18
|
Bausch Health Companies Inc. completes name change
|
pdf
|
|
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
|
07/09/18
|
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
|
PDF
|
|
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)
|
06/26/18
|
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)
|
PDF
|
|
FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion
|
06/18/18
|
FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion
|
PDF
|
|
Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops
|
06/14/18
|
Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops
|
PDF
|
|
Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins
|
06/12/18
|
Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins
|
PDF
|
|
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes
|
06/01/18
|
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes
|
PDF
|
|
Salix To Highlight New Clinical Data During Digestive Disease Week
|
05/31/18
|
Salix To Highlight New Clinical Data During Digestive Disease Week
|
PDF
|
|
Valeant Announces Pricing Of Private Offering Of Notes
|
05/17/18
|
Valeant Announces Pricing Of Private Offering Of Notes
|
PDF
|
|
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans
|
05/17/18
|
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans
|
PDF
|
|
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
|
05/15/18
|
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
|
PDF
|
|
Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference
|
05/10/18
|
Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference
|
PDF
|
|
Valeant To Seek Refinancing of its Existing Credit Agreement
|
05/10/18
|
Valeant To Seek Refinancing of its Existing Credit Agreement
|
PDF
|
|
Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance
|
05/08/18
|
Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance
|
pdf
|
|
Valeant Will Become Bausch Health Companies Inc.
|
05/08/18
|
Valeant Will Become Bausch Health Companies Inc.
|
PDF
|
|
Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine
|
05/07/18
|
Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine
|
PDF
|
|
Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
|
05/07/18
|
Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
|
PDF
|
|
Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference
|
05/03/18
|
Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference
|
PDF
|
|
Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
|
05/02/18
|
Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
|
PDF
|
|
Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication
|
05/02/18
|
Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication
|
PDF
|
|
Valeant announces 2018 Annual Meeting Results
|
05/01/18
|
Valeant announces 2018 Annual Meeting Results
|
pdf
|
|
Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting
|
04/27/18
|
Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting
|
PDF
|
|
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE By ONE Program
|
04/19/18
|
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE By ONE Program
|
pdf
|
|
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
|
04/12/18
|
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
|
PDF
|
|
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
|
04/12/18
|
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
|
PDF
|
|
Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery
|
04/11/18
|
Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery
|
PDF
|
|
Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes
|
04/10/18
|
Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes
|
PDF
|
|
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology
|
04/09/18
|
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology
|
PDF
|
|
Valeant Will Release First-Quarter 2018 Financial Results On May 8
|
04/06/18
|
Valeant Will Release First-Quarter 2018 Financial Results On May 8
|
PDF
|
|
Salix Launches 'Let's Talk 2' IBS Awareness Campaign
|
04/03/18
|
Salix Launches 'Let's Talk 2' IBS Awareness Campaign
|
PDF
|
|
Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes
|
03/26/18
|
Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes
|
PDF
|
|
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
|
03/12/18
|
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
|
PDF
|
|
Valeant Announces Pricing of Private Offering of Senior Notes
|
03/12/18
|
Valeant Announces Pricing of Private Offering of Senior Notes
|
PDF
|
|
Valeant Announces Launch Of Private Offering Of Senior Notes
|
03/12/18
|
Valeant Announces Launch Of Private Offering Of Senior Notes
|
PDF
|
|
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
|
03/12/18
|
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
|
PDF
|
|
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
|
03/08/18
|
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
|
PDF
|
|
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
|
02/28/18
|
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
|
pdf
|
|
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
|
02/28/18
|
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
|
PDF
|
|
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
|
02/27/18
|
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
|
PDF
|
|
Ortho Dermatologics Presents An Analysis Of SILIQTM (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis
|
02/16/18
|
Ortho Dermatologics Presents An Analysis Of SILIQTM (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis
|
pdf
|
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment
|
02/14/18
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment
|
PDF
|
|
Salix provides update on FDA submission for PLENVU®*
|
02/09/18
|
Salix provides update on FDA submission for PLENVU®*
|
pdf
|
|
Salix provides update on FDA submission for PLENVU®*
|
02/09/18
|
Salix provides update on FDA submission for PLENVU®*
|
pdf
|
|
Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28
|
02/06/18
|
Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28
|
PDF
|
|
Valeant Will Reduce Debt By An Additional $200 Million
|
01/25/18
|
Valeant Will Reduce Debt By An Additional $200 Million
|
PDF
|
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
|
01/12/18
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
|
PDF
|
|
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
|
01/09/18
|
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
|
PDF
|
|
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System
|
01/08/18
|
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System
|
PDF
|
|
Valeant Pays Down $300 Million Of Senior Secured Term Loans
|
01/03/18
|
Valeant Pays Down $300 Million Of Senior Secured Term Loans
|
PDF
|
|
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
|
01/03/18
|
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
|
PDF
|
